INvestigation of STEnt grafts in patients with type B Aortic Dissection: Design of the INSTEAD trial—a prospective, multicenter, European randomized trial - 21/08/11
, Simona Zannetti, MD b, Barbara Barbieri, MD b, Stephan Kische, MD a, Wolfgang Schareck, MD a, Tim C. Rehders, MD aon behalf of the INSTEAD study collaborators1
This is a physician-driven study. The Medtronic Peripheral Vascular Division (Maastricht, The Netherlands) provides monitoring and statistical support and compensates for complete filing and follow-up of randomized patients.
Résumé |
Purpose |
This study describes the design of an ongoing randomized trial initiated to compare the 2-year outcome of uncomplicated type B aortic dissection when treated by endovascular implantation of a Medtronic Talent stent graft adjunctive to best medical treatment versus best medical treatment alone.
Methods |
Patients older than 18 years with type B aortic dissection as diagnosed by computed tomography or magnetic resonance angiography are randomized to either a thoracic aortic endoprosthesis and antihypertensive treatment, called “stent grafting,” or a tailored antihypertensive treatment, called “medical treatment.” Only patients in a clinically stable condition and without spontaneous thrombosis of the false lumen after 14 days of the index dissection are considered eligible for study inclusion.
Results |
Primary outcome measure is all-cause mortality. Secondary outcome variables include conversion to stent and/or surgery, induced thrombosis of the false lumen, cardiovascular morbidity, aortic expansion (>5 mm/y of maximum diameter including true and false lumina), quality of life, and length of intensive care unit and hospital stay. The study design calls for 136 patients to be randomized and monitored for 24 months.
Conclusions |
The INSTEAD trial is the first randomized trial investigating the role of endoluminal treatment of uncomplicated type B aortic dissection. By the end of December 2004, 125 patients were randomized, accounting for 92% of the target. Final results of the INSTEAD trial should be available in 2006.
Le texte complet de cet article est disponible en PDF.Plan
Vol 149 - N° 4
P. 592-599 - avril 2005 Retour au numéro
Article précédent
- Glucose-insulin-potassium and reperfusion in acute myocardial infarction: Rationale and design of the Glucose-Insulin-Potassium Study-2 (GIPS-2)
- Iwan C.C. van der Horst, Jorik R. Timmer, Jan Paul Ottervanger, Henk J.G. Bilo, Rijk O.B. Gans, Menko-Jan de Boer, Felix Zijlstra, on behalf of the GIPS Investigators
- Predictors of response to cardiac resynchronization therapy (PROSPECT)—study design
- Cheuk-Man Yu, William T. Abraham, Jeroen Bax, Eugene Chung, Michelle Fedewa, Stefano Ghio, Christophe Leclercq, Angel R. León, John Merlino, Petros Nihoyannopoulos, Dean Notabartolo, Jing Ping Sun, Luigi Tavazzi, On behalf of the PROSPECT Investigators
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?